Clinical Trials

Prolium Bioscience advances its T-cell engager, PRO-203, in trials for scleroderma and lupus, heralding a new, potent strategy against severe autoimmunity.

With compelling Phase 2b survival data, NeuroSense is advancing its multi-target ALS drug to a pivotal Phase 3 trial. A deep dive into the science and strategy.

A single drug receptor could treat cancer, psoriasis, and liver disease. Can-Fite’s new scientific validation boosts its platform, but clinical and financial hurdles loom.

MapLight's Phase 2 trial for ASD missed its primary goal, but a powerful signal in reducing irritability in teens could reshape its future and offer a safer alternative.

Merck's positive Phase 3 results for tulisokibart signal a new era for UC care, targeting both fibrosis and inflammation in a potential first-in-class win.

With FDA clearance for its first-in-class remyelination drug, Scottish biotech Pheno Therapeutics is moving beyond inflammation to repair neurological damage.

A new enzyme blend for dogs boasts a 92% success rate in a clinical trial. We analyze the data and what it means for the pet supplement industry's future.

Replicate Bioscience’s new Gates Foundation grant isn't just about funding; it's a strategic move to deploy novel srRNA technology for global vaccine equity.

With a seasoned regulatory expert at the helm, Arletta Pharma is betting on its dual-action therapy, Lybrido, to transform the underserved FSIAD market.

A strategic pharma alliance scores a major win in Japan's lucrative neurology market, signaling a new competitive front and hope for thousands of patients.

A prestigious award for its ASD therapy Speragen puts Korean biotech Astrogen in the spotlight. Now, the firm faces the gauntlet of regulatory approval and market entry.

Companies like eGenesis are turning science fiction into reality with gene-edited pig organs. This is the story of a medical revolution at a crossroads.

With a key webinar ahead, Arrowhead Pharma is showcasing a trio of gene-silencing drugs. Can its TRiM™ platform upend a multi-billion dollar cardiometabolic market?

Memo Therapeutics' Potravitug shows promise in a Phase II trial, offering the first real weapon against a common virus that threatens kidney transplants.

A new patent gives CervoMed a long runway for its dementia drug, but can this IP victory secure the massive funding needed to cross the finish line?

As Oncoinvent accelerates its Phase 2 trial, a novel alpha-emitter therapy shows promise against a deadly cancer, signaling progress in radiopharmaceuticals.

AB Science has secured a US patent until 2042 for masitinib, a targeted therapy for advanced prostate cancer, offering new hope where few options exist.

A new network aims to speed up clinical trials by recruiting patients from med spas and longevity clinics. Is this the future of medicine or a risky new frontier?

A key regulatory win in Abu Dhabi opens a new international front for NeOnc's war on brain tumors, backed by novel science and significant insider buying.

A new partnership between Medventions and Mitacs aims to fix Canada's innovation gap by embedding engineers directly into clinics. Here's how it works.